Vol 81, Supp. II (2023): Zeszyty Edukacyjne 2/2023
Opinie i stanowiska ekspertów
Published online: 2024-02-06
Identyfikacja i leczenie pacjenta z niewydolnością serca z zachowaną frakcją wyrzutową lewej komory. Opinia ekspertów Asocjacji Niewydolności Serca Polskiego Towarzystwa Kardiologicznego
Abstract
Rozpoznanie niewydolności serca z zachowaną frakcją wyrzutową lewej komory (HFpEF) może sprawiać trudności wobec faktu heterogenności obrazu klinicznego tej populacji chorych, obciążeń chorobami współistniejącymi oraz ograniczonego wykorzystania podstawowych metod diagnostycznych, do których należą oznaczenia peptydów natriuretycznych oraz czynnościowe testy diagnostyczne. Niniejszy dokument podsumowuje aktualny stan wiedzy w zakresie identyfikacji i leczenia pacjenta z HFpEF z uwzględnieniem opublikowanych w ostatnim czasie europejskich oraz amerykańskich dokumentów i ma na celu ułatwić lekarzom praktykom rozpoznanie HFpEF.
Keywords: niewydolność sercaniewydolność serca z zachowaną frakcją wyrzutową lewej komory
References
- Savarese G, Lund LH, et al. Global public health burden of heart failure. Card Fail Rev. 2017; 3(1): 7–11.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79(17): e263–e421.
- Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023; 81(18): 1835–1878.
- Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021; 23(3): 352–380.
- Docherty KF, Lam CSP, Rakisheva A, et al. Heart failure diagnosis in the general community — who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2023; 25(8): 1185–1198.
- Tromp J, van der Meer P, Tay W, et al. Diagnostic accuracy of the electrocardiogram for heart failure with reduced or preserved ejection fraction. J Card Fail. 2023; 29(7): 1104–1106.
- Pieske B, Tschöpe C, Boer Rde, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019; 40(40): 3297–3317.
- Smiseth OA, Morris DA, Cardim N, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2022; 23(2): e34–e61.
- Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018; 138(9): 861–870.
- Reddy YNV, Kaye DM, Handoko ML, et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol. 2022; 7(9): 891–899.
- Mandviwala TM, Basra SS, Khalid U, et al. Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. Int J Obes (Lond). 2020; 44(7): 1561–1567.
- Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006; 151(5): 999–1005.
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021; 23(4): 512–526.
- Díez-Villanueva P, Jiménez-Méndez C, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol. 2021; 18(3): 219–232.
- Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-Specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016; 134(1): 73–90.
- Elkammash A, Tam SS, Yogarajah G, et al. Management of heart failure with preserved ejection fraction in elderly patients: effectiveness and safety. Cureus. 2023; 15(2): e35030.
- Tibrewala A, Yancy CW. Heart failure with preserved ejection fraction in women. Heart Fail Clin. 2019; 15(1): 9–18.
- Sotomi Y, Hikoso S, Nakatani D, et al. Sex differences in heart failure with preserved ejection fraction. J Am Heart Assoc. 2021; 10(5): e018574.
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451–1461.
- Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022; 387(12): 1089–1098.
- McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023; 44(37): 3627–3639.
- Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022; 400(10354): 757–767.
- Lelonek M, Grabowski M, Kasprzak JD, et al. An expert opinion of the Heart Failure Association of the Polish Cardiac Society on the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure: Heart failure guidelines from a national perspective. Kardiol Pol. 2022; 80(2): 239–246.
- Nessler J, Krawczyk K, Leszek P, et al. Expert opinion of the Heart Failure Association of the Polish Society of Cardiology, the College of Family Physicians in Poland, and the Polish Society of Family Medicine on the peri discharge management of patients with heart failure. Kardiol Pol. 2023; 81(7-8): 824–844.
- Anker SD, Usman MS, Anker MS, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. 2023; 25(7): 936–955.
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023; 389(12): 1069–1084.
- Verma S, Borlaug BA, Butler J, et al. A big STEP for treatment of heart failure with preserved ejection fraction. Cell Metab. 2023; 35(10): 1681–1687.
